TG4001 2024
Category: Press release
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
SITC 2024
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
H1 2024 FINANCIAL RESULTS
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
BT-001 ESMO
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
Nominations
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
ESMO ABSTRACT
Transgene to Participate in HTID Conference and Investor Access Forum in Paris
investor events
Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
TG6050
Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
current account advance
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
BT-001 ESMO 2024
